Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
66/434
Matches for
“NashTest-2”
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.
…The performances of the FibroTest, NashTest-2 and SteatoTest-2 were assessed…
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
…When the two groups were pooled together the NashTest Sp for NASH…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
…2 and NashTest-2 were all equivalent in 136 type-2-diabetes…
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
-
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.
…SteatoTest, NashTest and FibroTest) were used to assess steatosis, nonalcoholic steatohepatitis (NASH…
-
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.
…comprising components including the SteatoTest, NashTest and FibroTest) through three randomized sham…
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
…Data collected included anthropometrics, biochemistry, adiponectin, SteatoTest™, NashTest™, FibroTest™, OWLiver® test and…
-
The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.
…NashTest scores is as following: N0--56.6%, N1--38.2% and…
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
…Finally, the authors assessed the diagnostic role of ActiTest and NashTest 2…
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
…for TD-SWE, 1.2% for NashTest-T2D, and 0.02% for…
-
FibroMAX: towards a new universal biomarker of liver disease? Review
…viral hepatitis C and B; NashTest (BioPredictive) for the categorical diagnosis of…
-
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
…Methods Noninvasive blood tests (SteatoTest, NashTest, and FibroTest) were used to evaluate…
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
…The performance of the SteatoTest-2 was compared with the reference test…
-
The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.
…5.2%, H2 - 0%, and H3 - 0.7%, while for NashTest was…
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Meta Analysis
…54.2%, and steato-hepatitis (NAS score >4) 17.2%. The mean…
-
Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.
…NASHTest®, before and after surgery. ### Results Fibrosis' prevalence was 74.2% with…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.
…FibroMax® panels (i.e., SteatoTest®, FibroTest®, NashTest®, and ActiTest®) were determined from…
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
…The performance of the ActiTest and NashTest-2 to diagnose definite NASH…
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
### Background Although the FibroTest has been validated as a biomarker to determine…
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.
…calcification in individuals with type 2 diabetes (T2D) remains unclear. This study…
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
…FibroTest), steatosis (SteatoTest), and steatohepatitis (NashTest, ActiTest) in these patients. ### Materials And…
-
Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.
Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…
-
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
…All had hepatic MRI-PDFF, FibroScan/CAP, FibroTest/NashTest/SteatoTest, APRI, FIB…
-
Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.
…the FibroTest, SteatoTest and NashTest, from the Fibromax® panel. Among the main…
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
…2.3±1.8; 3±2.6 and 3.8±2.7…
-
The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.
…2.80 and 0.18 for NASH. As compared versus SteatoTest, NashTest…
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
…2.07-2.77, _p_ < 0.00001) and body mass index (BMI…
-
Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
### Background In recent years noninvasive methods have been evaluated for the assessment…
-
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
…Patients had mild (16.2%), moderate (69.9%), or severe (13.9…
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.
-
Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
…LVDD) in patients with type 2 diabetes mellitus (T2DM). **Methods**: This single…
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
…The prevalence of presumed fibrosis was 2.8%, (209/7,463), including…
-
Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.
…mortality (Hazard ratio [95% CI]: 2.75 [1.26; 6.03]) than…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
**Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…
-
Biomarkers of liver fibrosis. Review
Liver biopsy, due to its limitations and risks, is an imperfect gold…
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
### Background Blood tests of liver injury are less well validated in non…
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
…Advanced fibrosis was identified by FT in 53/1909 (2.8%) hyperlipidaemic…
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Review
### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
…male gender (Relative Risk=3.29), HIV co-infection (2.33), and…
-
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
…ALT, cytokeratin-18, NashTest 2, HAIR, BARD, and OWLiver; advanced fibrosis: AST…
-
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.
### Background & Aims There is controversy about the performance of noninvasive tests such…
-
Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
…White male methadone-users had 2.1-fold excess advanced inflammation risk…
-
Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?
-
Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.
…Haptoglobin, ALT, gamma GT, alpha-2-macroglobulin, apolipoprotein A1 and bilirubin, required…
-
Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
…Most subjects (84.2%) with FLI < 60 had S0 and none had…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
…The presence of advanced fibrosis [HR (95% CI)] [2.98 (95% CI…
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
…This resulted in twice as many cases of cirrhosis being detected, 2…
-
Assessment of liver fibrosis: noninvasive means.
…Among a total of 2,237 references, a total of 14 validated…
-
Noninvasive evaluation of NAFLD. Review
A common clinical concern in patients with NAFLD is whether they have…
-
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
…In the population with type 2 diabetes who were 45 years or…
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Review
The correct identification of patients at increased risk of non-alcoholic steatohepatitis…
-
Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.
### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…
-
Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.
### Background Steatosis is common in patients with hepatitis C virus (HCV) infection…
-
Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.
…had a validity of 90.2% (95% CI AUROC = 0.831-0…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
…Serious adverse events related to therapy were reported in 61/2070(2…
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
…95% of patients received prednisolone; and the 2-year mortality was 63…
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
…Assessment of Diagnostic Accuracy Studies-2. ### Results In total, 138 articles were…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.
### Background One of the unmet needs in patients with metabolic risks is…
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Meta Analysis
### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
…For the diagnosis of grade 2-4 steatosis, the sensitivity of SteatoTest…
-
[Biomarkers for liver fibrosis: advances, advantages and disadvantages]. Review
Liver cirrhosis in Mexico is one of the most important causes of…
-
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Meta Analysis
…80 (72-86%), and 6.2% (3.3-11.9), respectively. The…
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.
…or without type 2 diabetes mellitus (T2DM), alpha-2 macroglobulin (A2M), apolipoprotein…
Showing the full result list. The page is server-rendered and not paginated.